ClinicalTrials.gg
TerminatedNCT02413489Updated Feb 4, 2025Results posted

An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

A Phase 2 interventional study of Daratumumab in Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse and Lymphoma, Follicular, sponsored by Janssen Research & Development, LLC. Terminated at 35 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Why this study was terminated
DLBCL and FL cohorts met the pre-specified futility criteria and will not proceed. The MCL cohort was terminated due to slow recruitment and aggressive disease.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson — none open to participants now, 1 under way, 1 of them phase 3. Lymphoma, Mantle-Cell · Johnson & Johnson.

Enrollment
7th of 12
36 · median 48
Started
2015
with 2 others
Phase 2
4 of 16
none open now
Registered
9th of 16
by date

Among the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2015, is one of 4 in phase 2, and was the 9th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

None of the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson is open now. The open studies under Lymphoma, Mantle-Cell, anywhere →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson as a file.
02

Study summary

The purpose of this study is to assess overall response rate [ORR, including complete response (CR) and partial response (PR)], of daratumumab in participants with non-Hodgkin's lymphoma [a cancer of the lymph nodes (or tissues)-NHL] and to evaluate association between ORR and CD38 expression level in order to determine a threshold for CD38 expression level in each NHL subtype, above which daratumumab activity is enhanced in participants with relapsed or refractory mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.

Read the detailed description

This is an open label (everyone knows the study intervention), Phase 2 study to evaluate efficacy and safety of daratumumab in relapsed or refractory mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. The study will have three phases. Screening phase, treatment phase, follow-up phase. Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion approximately 3.5 years. Participants will primarily be assessed for overall response rate. Safety will be monitored throughout the study.

03

Conditions studied

  • Lymphoma, Mantle-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Follicular

Keywords

  • Lymphoma, Mantle-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Follicular
  • Daratumumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has diagnosis and prior treatment for each non-hodgkin's lymphoma (NHL) subtype as defined below: Mantle cell lymphoma (MCL): verified diagnosis of MCL based on local pathology report, disease after at least 2 , including at least 1 cycle of Bruton's tyrosine kinase (BTK) inhibitor therapy and documented progressive disease (PD) during or after BTK inhibitor treatment or participants who could not tolerate BTK inhibitor [ie, discontinued BTK inhibitor due to adverse events (AEs)], b) Diffuse large B cell lymphoma (DLBCL): pathologically confirmed diagnosis of non-transformed DLBCL, and relapsed or refractory disease; for those participants who have not received HDT/ are not eligible for HDT/ASCT due to comorbidities, c) Follicular lymphoma (FL): pathologically confirmed diagnosis of FL of Grade 1, 2, or 3a according to World Health Organization (WHO) criteria without pathological evidence of transformation, and relapsed disease after at least two prior systemic therapies including one anti-CD20 containing combination regimen
  • At least 1 measurable site of disease
  • Participants must have available archival or fresh tumor tissue or both to submit to a central laboratory for CD38 assay. Expression of CD38 is measured by immunohistochemistry on fresh or archived tumor sample by central assessment using a CD38 IHC assay under development: a) Stage 1: participants whose tumors are more than or equal to (>=) 50 percent (%) positive for CD38, b) Stage 2: participant has less than (\<) 50% CD38+ or greater than (>) 50% CD38+ depending on the distribution of CD 38 expression of enrolled participants during Stage 2. The sponsor will advise on which eligibility criterion is permitted during the enrollment period
  • Participant must have an performance status score of 0 or 1
  • Women of must be practicing a highly effective method of consistent with local regulations regarding the use of birth control methods for participants participating in clinical studies: example, established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS); barrier methods: condom with spermicidal foam/gel/film/cream/suppository or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; male partner sterilization (the vasectomized partner should be the sole partner for that participant); true abstinence (when this is in line with the preferred and usual lifestyle of the participant) during and after the study (3 months after the last dose of any component of the treatment regimen)
  • A woman of childbearing potential must have a negative serum or urine pregnancy test within 14 days before commencing treatment. Females of must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously
  • A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control example, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of any component of the treatment regimen. The exception to this restriction is that if the participant's female partner is surgically sterile, a second method of birth control is not required

Exclusion criteria

Exclusion Criteria:

  • Known central nervous system lymphoma
  • Prior anti-tumor therapy including (all times measured prior to start of study drug): nitrosoureas within 6 weeks, chemotherapy within 3 weeks, therapeutic antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy within 2 weeks, agents within 3 weeks, unless antibody this should be within 4 weeks
  • Daratumumab or other anti-CD38 therapies
  • Participant has a history of (other than NHL) within 3 years before the screening period (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, non-muscle invasive bladder cancer (papillary neoplasms of low malignant potential and primary non-invasive tumors), or malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 2 years)
  • Participant has known (COPD) with a (FEV1) less than (\<) 50% predicted normal. Note that FEV1 testing is required for participants suspected of having COPD and participants must be excluded if FEV1 \<50% b) Participant has known moderate or severe persistent asthma within 2 years (see Attachment 4: NHLBI table of asthma severity), or currently has uncontrolled asthma of any classification. (Note that participants who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Daratumumab

    Participants will receive daratumumab (16 milligram per kilogram \[mg/kg\]) as intravenous infusion once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.

    Drug: Daratumumab

Interventions

  • Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR). As per Revised Response Criteria for Malignant Lymphoma, Lymph node measurements were taken from Computed Tomography (CT), CT portion of the Positron Emission Tomography/Computed Tomography (PET/CT), or Magnetic resonance imaging (MRI) scans where applicable. CR is defined as complete disappearance of all evidence of disease; PR as a greater than (\>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.

    Time frame: After the first dose until disease progression, withdrawal of consent from study participation, or the end of study (approximately 1.9 years)

Secondary outcomes

  1. Duration of Response

    Duration of response was the duration from the date of the initial documentation of a response to the date of first documented evidence of progressive disease (PD). PD is defined as any new lesion \>1.5 centimeter (cm) in any axis or greater than or equal to (\>=) 50% increase in previously involved sites.

    Time frame: Approximately 1.9 years

  2. Progression Free Survival (PFS)

    PFS was defined as the duration from the date of the first daratumumab dose to the date of progression or death, whichever comes first.

    Time frame: Approximately 1.9 years

  3. Overall Survival (OS)

    Overall survival was defined as the duration from the date of the first daratumumab dose to the date of death.

    Time frame: Approximately 1.9 years

  4. Time to Response

    Time to response was defined as the duration from the date of the first dose of daratumumab to the earliest date that a response (CR/PR) is first documented.

    Time frame: Approximately 1.9 years

07

Results

Posted Jun 26, 2018
Limitations and caveats
The study was terminated due to 2 non-Hodgkin's lymphoma (NHL) sub types (DLBCL and FL cohorts) meeting the futility criteria defined in the protocol and the MCL cohort not having adequate recruitment.

Participant flow

Participant flow — Overall Study
MilestoneDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)
Started15165
Completed000
Not completed15165
Withdrew: Death1134
Withdrew: Withdrawal by subject200
Withdrew: Study terminated by sponsor2131

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR). As per Revised Response Criteria for Malignant Lymphoma, Lymph node measurements were taken from Computed Tomography (CT), CT portion of the Positron Emission Tomography/Computed Tomography (PET/CT), or Magnetic resonance imaging (MRI) scans where applicable. CR is defined as complete disappearance of all evidence of disease; PR as a greater than (\>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.

Time frame:
After the first dose until disease progression, withdrawal of consent from study participation, or the end of study (approximately 1.9 years)
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)
Overall Response Rate (ORR)6.7 (0.2 to 31.9)12.5 (1.6 to 38.3)0 (NA to NA)
SecondaryDuration of Response

Duration of response was the duration from the date of the initial documentation of a response to the date of first documented evidence of progressive disease (PD). PD is defined as any new lesion \>1.5 centimeter (cm) in any axis or greater than or equal to (\>=) 50% increase in previously involved sites.

Time frame:
Approximately 1.9 years
Reported as:
Number · Months
Duration of Response
MonthsDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)
Participant 11.60.7—
Participant 2NA7.4—
SecondaryProgression Free Survival (PFS)

PFS was defined as the duration from the date of the first daratumumab dose to the date of progression or death, whichever comes first.

Time frame:
Approximately 1.9 years
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)
Progression Free Survival (PFS)1.2 (0.6 to 1.7)3.3 (1.9 to 3.8)1.3 (0.5 to 1.9)
SecondaryOverall Survival (OS)

Overall survival was defined as the duration from the date of the first daratumumab dose to the date of death.

Time frame:
Approximately 1.9 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)
Overall Survival (OS)4.9 (2.1 to 9.0)17.2 (15.0 to NA)4.8 (1.7 to NA)
SecondaryTime to Response

Time to response was defined as the duration from the date of the first dose of daratumumab to the earliest date that a response (CR/PR) is first documented.

Time frame:
Approximately 1.9 years
Reported as:
Number · Months
Time to Response
MonthsDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)
Participant 11.92.3—
Participant 2NA1.9—

Adverse events

Collected over Up to 1.9 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Diffuse Large B-cell Lymphoma (DLBCL)11/15 (73.3%)6/15 (40%)15/15 (100%)
Follicular Lymphoma (FL)3/16 (18.8%)6/16 (37.5%)16/16 (100%)
Mantle Cell Lymphoma (MCL)4/5 (80%)3/5 (60%)5/5 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)
PyrexiaGeneral disorders0/150/162/5
Febrile NeutropeniaBlood and lymphatic system disorders0/151/161/5
General Physical Health DeteriorationGeneral disorders1/150/161/5
ThrombocytopeniaBlood and lymphatic system disorders1/150/160/5
Abdominal Pain LowerGastrointestinal disorders1/150/160/5
PneumoniaInfections and infestations1/151/160/5
Decreased AppetiteMetabolism and nutrition disorders1/150/160/5
Musculoskeletal PainMusculoskeletal and connective tissue disorders1/150/160/5
Acute Kidney InjuryRenal and urinary disorders1/150/160/5
Chronic Kidney DiseaseRenal and urinary disorders1/150/160/5
Most frequent other events
Showing 10 of 142
Most frequent other events
EventDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)
CoughRespiratory, thoracic and mediastinal disorders7/156/164/5
NauseaGastrointestinal disorders5/151/162/5
Muscle SpasmsMusculoskeletal and connective tissue disorders0/151/162/5
DyspnoeaRespiratory, thoracic and mediastinal disorders1/152/162/5
Throat IrritationRespiratory, thoracic and mediastinal disorders0/152/162/5
AnaemiaBlood and lymphatic system disorders1/155/161/5
Abdominal PainGastrointestinal disorders2/155/161/5
HeadacheNervous system disorders0/155/161/5
VomitingGastrointestinal disorders4/150/161/5
FatigueGeneral disorders4/153/161/5

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Total
<=18 years0000
Between 18 and 65 years59418
>=65 years107118
Age, Continuous
Age, Continuous(years)Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Total
Mean66.7 ± 11.8862.3 ± 9.7759.8 ± 6.6963.8 ± 10.45
Sex: Female, Male
Sex: Female, Male(Participants)Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Total
Female65011
Male911525
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Total
Hispanic or Latino0123
Not Hispanic or Latino1215229
Unknown or Not Reported3014
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Total
Asian4206
White713222
Unknown1001
Not Reported3115
Other0022
Region of Enrollment
Region of Enrollment(Participants)Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Total
Australia0202
Belgium2002
France4206
Netherlands2327
Republic of Korea4206
Turkey2215
United States1528
CD38 expression value
CD38 expression value(Percentage of CD38 expression)Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Total
Mean76.3 ± 18.0770.3 ± 16.7864 ± 8.2271.9 ± 16.66
08

Study locations

35 sites
  • Duarte, California, United States
  • Fountain Valley, California, United States
  • Jacksonville, Florida, United States
  • Pembroke Pines, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Louisville, Kentucky, United States
  • Baltimore, Maryland, United States
  • Rochester, Minnesota, United States
  • Omaha, Nebraska, United States
  • New Brunswick, New Jersey, United States
  • Pittsburgh, Pennsylvania, United States
  • Houston, Texas, United States
  • Seattle, Washington, United States
  • Adelaide, Australia
  • Box Hill, Australia
  • Melbourne, Australia
  • Brugge, Belgium
  • Gent, Belgium
  • Lille, France
  • Limoges Cedex, France
  • Nantes Cedex 01, France
  • Paris Cedex 10, France
  • Pessac, France
  • Pierre Benite, France
  • Rouen Cedex, France
  • Goyang si, Korea, Republic of
  • Seoul, Korea, Republic of
  • Amsterdam, Netherlands
  • Rotterdam, Netherlands
  • Utrecht, Netherlands
  • Ankara, Turkey
  • Atakum, Turkey
  • Istanbul, Turkey
  • Kocaeli, Turkey
09

References and documents

Publications

  • Salles G, Gopal AK, Minnema MC, Wakamiya K, Feng H, Schecter JM, Wang M. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 May;19(5):275-284. doi: 10.1016/j.clml.2018.12.013. Epub 2019 Jan 2. PubMed 30795996 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Jun 2017, 20 months.

Results were first posted in Jun 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2015
First posted
Apr 10, 2015
StartActual
Sep 2, 2015
Primary completionActual
Jun 1, 2017
CompletionActual
Jun 1, 2017
Results first posted
Jun 26, 2018
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02413489
Responsible party
Sponsor
First posted
Apr 10, 2015
Start date
Sep 2, 2015
Primary completion
Jun 1, 2017
Completion
Jun 1, 2017
Results posted
Jun 26, 2018
Last update
Feb 4, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion